NCT02944500View on ClinicalTrials.gov

Saxenda: Underlying Mechanisms and Clinical Outcomes

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Obesity

Interventions

DRUG

liraglutide

OTHER

Placebo

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center General Clinical Research Center, Boston

All Listed Sponsors

lead

Beth Israel Deaconess Medical Center

OTHER